Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.
Navin R PintoSteven G DuBoisAraz MarachelianScott J DiedeAgne TaraseviciuteJulia L Glade BenderDenice Tsao-WeiSusan G GroshenJoel M ReidDaphne A Haas-KoganC Patrick ReynoldsMin H KangMeredith S IrwinMargaret E MacyJudith G VillablancaKatherine K MatthayJulie R ParkPublished in: Pediatric blood & cancer (2018)
Increased dose vorinostat (430 mg/m2 /day) on an interrupted schedule is tolerable in combination with isotretinoin. This dose led to increased vorinostat exposures and demonstrated increased histone acetylation. Prolonged stable disease in patients with minimal residual disease warrants further investigation.